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Abstract: There is a current unmet medical need for the treatment of antibiotic-resistant infections,
and in the absence of approved alternatives, some clinicians are turning to empirical ones, such as
phage therapy, for compassionate treatment. Phage therapy is ideal for compassionate use due to its
long-standing historical use and publications, apparent lack of adverse effects, and solid support
by fundamental research. Increased media coverage and peer-reviewed articles have given rise
to a more widespread familiarity with its therapeutic potential. However, compassionate phage
therapy (cPT) remains limited to a small number of experimental treatment centers or associated with
individual physicians and researchers. It is possible, with the creation of guidelines and a greater
central coordination, that cPT could reach more of those in need, starting by increasing the availability
of phages. Subsequent steps, particularly production and purification, are difficult to scale, and
treatment paradigms stand highly variable between cases, or are frequently not reported. This article
serves both to synopsize cPT publications to date and to discuss currently available phage sources for
cPT. As the antibiotic resistance crisis continues to grow and the future of phage therapy clinical trials
remains undetermined, cPT represents a possibility for bridging the gap between current treatment
failures and future approved alternatives. Streamlining the process of cPT will help to ensure high
quality, therapeutically-beneficial, and safe treatment.
Keywords: bacteriophage therapy; compassionate use; antibiotic resistance
1. Introduction
The first documented therapeutic case of harnessing the natural antibacterial mechanism of
bacteriophages, or phages, for the treatment of a human bacterial infection predates the discovery of
antibiotics by two decades [1]. Phages were used experimentally for the treatment of various bacterial
infections throughout the 1920s, including cholera (reviewed in [2]), dysentery [3], and staphylococcal
infections [4] to varying degrees of success [5,6]. For these early applications, phages needed to be
isolated from environmental sources, cultivated on bacterial hosts, and purified in line with technology
at the time. The deemed founder of phage therapy, F. d’Hérelle, had a heavy hand in the spread of
phage therapy during these early years, which he encouraged by traveling to different countries, such
as the Soviet Union, India, Egypt, and others, bringing with him phages and the knowledge of how to
use them against human bacterial infections [2,7,8].
As phages fell to the wayside with the pursuit of antibiotics in Western medicine in the 1940s, Soviet
researchers continued phage development at the G. Eliava Institute of Bacteriophages, Microbiology,
and Virology in Tbilisi, Georgia [7,9]. There, phages were isolated from environmental sources and
accumulated into a phage bank that exists to this day. This collection provides a large repertoire from
which phages can either be incorporated into pre-formulated products or selectively matched against
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bacterial isolates for personalized therapies. As a result of historical clinical trials and experience
accrued during the twentieth century, phages exist alongside antibiotics as approved medicines in
some former Soviet Union countries. However, historical data from one country holds little scientific
weight in present day evaluations of unapproved medicines in others.
Now, the rest of the world has a re-found interest in revitalizing phage therapy that has paralleled
the rise of antibiotic resistance [10–14]. For phage therapy to be recognized as an effective alternative
to antibiotics, it will require efficacy data from randomized, controlled clinical trials (RCTs). The three
phage RCTs completed to date have failed to produce robust conclusions on efficacy, therefore leaving
phage therapy in limbo in the approval process until future trials are conducted [15–17]. Only one
RCT for phage products is currently open for enrollment (ClinicalTrials.gov Identifier: NCT03808103),
although several are scheduled for patient enrollment in the near future. In the interim, several
competency centers, physicians, and researchers are invoking phage therapy for compassionate means
in order to respond to the current clinical needs of patients suffering from antibiotic failure.
2. Compassionate Use
Compassionate treatment denotes the use of unapproved medicines outside of clinical trials for
the treatment of patients for which approved therapeutic options have been exhausted. The principle
of compassionate use is codified in the “Helsinki Declaration of Ethical Principles for Medical Research
Involving Human Subjects”, which is an international agreement on facets of clinical research, such
as patient consent and placebo control [18]. Article 37 specifically asserts a physician’s authority to
act in the best interest of their patient by using experimental treatments in the absence of approved
options, although the support of using unproven treatments was not stipulated by the Declaration
until its amendment in 2000 (v2000, Article 32) [19]. In its current state, it reads in its entirety, “In the
treatment of an individual patient, where proven interventions do not exist or other known interventions have
been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally
authorised representative, may use an unproven intervention if in the physician’s judgement it offers hope of
saving life, re-establishing health or alleviating suffering. This intervention should subsequently be made the
object of research, designed to evaluate its safety and efficacy. In all cases, new information must be recorded and,
where appropriate, made publicly available” [18].
The term “compassionate use” can therefore be referred to both vernacularly in this general sense,
as well as formally as a regulatory pathway (also referred to as “expanded access” or “special access”).
The process and conditions for compassionate use are stipulated by regulatory agencies, such as the
Food and Drug Administration (FDA) in the United States, the Therapeutic Goods Administration
(TGA) in Australia, or the European Medicines Agency (EMA) in the European Union (EU), although
EU member states apply EMA directives independently and may be governed by additional national
regulation [20–22]. The objective of compassionate treatment differs from RCTs in that its primary aim
is to provide therapeutic benefit to the patient, rather than to evaluate the efficacy of the experimental
treatment (although safety may be evaluated). While the term “compassionate” is frequently associated
with case reports of phage therapy, it does not inherently signify regulatory adherence, and legal
processes that are required for compassionate treatment vary from country to country [23].
The general prevalence and importance of compassionate use is changing, with an increase in
access requests and legal support [24–26]. Instigation of compassionate treatment also increasingly
arises from patient advocacy groups or patients via social media platforms, to bring attention to,
put pressure on, and finance access to unapproved therapies [27]. “Right-to-try” legislation in the
US aims to expedite treatment of severely ill patients with unapproved medicines, albeit with lower
regulatory and safety oversight [25]. While the intention is to increase therapeutic options for patients
and highlight the inability of current pathways to respond punctually to medical needs, it is not
without consequence for ethical considerations, such as equal access, unfulfilled expectations, data
collection/usage, or financial responsibility [23–25,28].
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3. Compassionate Phage Therapy (cPT)
The potential utility of cPT is considered after antibiotic failure is clearly documented, attempts to
use conventional treatment have been exhausted, and there are no active clinical trials suitable for
enrolment (Figure 1). The possibility of using phages may be suggested by the physician, medical
entourage, or the patient themselves. Both the consent of the physician and the patient or guardian are
essential for continuing the process of cPT, which may or may not be subject to additional institutional
or national regulation on the use of unapproved or experimental therapies. cPT has been approved
under emergency investigational new drug (eIND) and expanded access schemes by the FDA, a
temporary use authorization (ATU) by the French National Agency for Medicines and Health Products
Safety (ANSM) in France, by special access schemes by the TGA in Australia, and by national regulation
in Poland. Expanded/special access schemes facilitate access to products in clinical development for
compassionate treatments and several phage products have fallen under such schemes in the US and
Australia [29–31]. Without local support, physically- and financially-able patients have the option
of traveling to receive phage therapy in countries where it is an approved medicine: For instance,
the Eliava Institute in Tbilisi, Georgia has provided treatment to a number of international patients
on-site [32–34]. The exact process for organizing cPT remains highly variable at present due to its
compassionate nature. It can represent a time-consuming endeavor for new cases, to the extent that
it may deter motivation to pursue cPT as an option or delay the initiation of treatment, which may
influence therapeutic outcomes. Competency centers or individuals experienced with cPT have the
advantage of activating familiar pathways for subsequent treatments, and it is the experience of the
authors that these centers and individuals are generally willing to be consulted for information on
how to best initiate and follow through with cPT. The cost of providing a phage suitable for human
application is currently high, with the financial burden falling on the phage provider for most cPT
cases, although this may vary between countries and the regulatory status of phage therapy.
Figure 1. General process and considerations for compassionate phage therapy (cPT). Required steps
are shown in bold. Circular arrows indicate processes that are dynamic and do not occur necessarily in
a chronological order. PRV: Phage-resistant variant. AB: Antibiotic.
Some countries have established legislation for phage therapy without marketing approvals for
phage products, such as the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy
in Poland, which has been treating patients with phages experimentally with outpatient care since
the 1970s. The Phage Therapy Unit (PTU) was opened there in Poland in 2005, which operates phage
treatment under a national regulation scheme, and researchers have published summaries and case
reports on nearly 1500 patients since 2000 [35–40]. Costs for cPT are more realistically managed in
Poland, where research institutions, such as the PTU, are not permitted to cover healthcare-related costs,
leaving payment to the patients, insurance companies, or sponsors. The Center for Innovative Phage
Applications and Therapeutics (IPATH) at the University of California San Diego School of Medicine
opened mid-2018 as the only present-day phage center in North America with a clear intention of using
phages for compassionate needs and for the eventual elaboration of clinical trials [41]. Experience
with several cPT treatments in Belgium led to a recently orchestrated permission to use phages as
active ingredients of magistral preparations (known as compounded prescription drugs in the US) [42].
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This framework allows phages to be prescribed for individual patients as long as they are produced
according to an internal monograph. Phages are still considered “non-authorized” components of the
preparation, however, and the availability of magistral phage preparations is still limited, even within
Belgium. While this model is distinct from compassionate use, it illustrates how compassionate use
can lead to the elaboration of alternative approval pathways with clearly-defined guidelines, even if
they are unlikely to be replicated in countries, such as the US, where compounded components require
authorizations. Beyond such phage competency centers, unassociated physicians have occasionally
independently administered phages from academic, biotech, and commercial sources for the treatment
of antibiotic resistant infections [32,43–47].
There are more than 25 reports of cPT since 2000, half of which have been published in the
past two years and represent different infections, phages, pathogens, and administration routes that
collectively represent the application of phages to nearly 2000 people (Table 1). These case studies are
published either as periodic updates on the experiences of competency centers or zealous physicians
or researchers, or as isolated one-off applications. They vary widely in the information included
within the publication, concerning treatment outcomes, concomitant antibiotic use, and microbiological
assessment. Instances of cPT usually incur a lag time to publication or are presented at conferences
or published as press releases rather than peer-reviewed publications, meaning that there are more
cPT cases occurring than published through scientific channels. Indeed, Ampliphi Biosciences have
announced via press-release an 84% clinical success rate through their expanded access programs for
the treatment of Staphylococcus aureus or Pseudomonas aeruginosa infections [30,48].
From published cases, treatment with cPT for S. aureus infections has been reported the most
frequently, followed by P. aeruginosa and Escherichia coli, and to a lesser extent, Enterococcus sp., and
Acinetobacter baumannii (Table 1). Cases include the treatment of a myriad of different indications for
both chronic and acute conditions, including bone-and-joint, urogenital, respiratory, wound, cardiac,
and systemic infections, via various administration routes. Positive treatment outcomes range from
40 to 100% of patients included in reports of more than one participant, depending on the size of the
study and heterogeneity of treatment strategies (monotherapy versus cocktail; phage substitution;
combination with antibiotics). The development of resistance to applied phages was microbiologically
documented in only five reports and largely uninvestigated or unreported in most studies, even in
the event of unsatisfactory clinical outcomes. Larger reports show treatment failure rates between 4%
and 60%, again with differing methodology between studies with little analytical explanation as to
how or why failure occurred. Even definitions of clinical “success” or “failure” may vary, therefore
cautioning against the over-interpretation of some cPT results. While publishing cases of cPT helps
foster familiarity with phage therapy and support claims of safety, it is not possible to draw conclusions
on broader efficacy or to use compassionate treatments in lieu of clinical trials. More standardized
reporting guidelines would, however, be useful in order to make comparisons between treatments,
particularly in terms for the development of phage resistance (Oechslin and McCallin, submitted).
Viruses 2019, 11, 343 5 of 14
Table 1. Summary of 29 publicly-available, published cases of cPT as of April 2019 in chronological
order of most recent publication. Causative pathogens, types of infections (mono/polymicrobial; clinical
indication), and administration routes vary between studies. The definition of success may be specific
to authors, but overall indicates observed clinical amelioration and/or pathogen clearance. Concomitant
antibiotic therapy is indicated for the number of patients per study if ≥1. Plausible reasons for cPT
failure are listed when available, as well as the investigation into bacterial development of resistance to
applied phages. Phage sources used for treatment are listed and further information can be found in
cited references.
Pathogen Infection Admin Route N* ClinicalOutcome AB (N*)
Failure
/PRV+
Phage
Source Ref.
A. baumannii,
K. pneumoniae Bone iv 1 Success Yes na/no Military [49]
S. aureus;
P. aeruginosa;
E. coli; ProteusPM
Bone; GI;
ENT;
urogenital
Local; oral;
rectal; joint
injection
15
High success
rate (12/15); all
cases improved
Yes
2◦ pathogen for 1
patient; unclear
results for 2
patients
Mostly
commercial [33]
S. aureus Bone Soft-tissueinjection 1 Success Int. na/nr
Commercial
(Eliava) [45]
S. aureus; E. coli;
Proteus;
Streptococcus;
P. aeruginosa
UTI Local viacatheter 9
Bacterial load
decrease in 67%
(6/9); pathogen
clearance for 3
patients
Yes (1)
No decrease for
1 patient; 2◦
infection for
1 patient/ nr
Commercial
(Eliava);
adapted
to strains
[50]
Achromabacter
xylosoxidans
Cystic
Fibrosis
infection
Inhaled; oral 1
Improved lung
function and
general
condition
Yes, post na/nr Environ. [51]
P. aeruginosa Recurrentpneumonia Inhaled; iv 1 Success Yes na/ Yes (PS)
Environ.,
biotech;
military
[52]
S. aureus Bone Local 1 Success Yes na/nr Biotech
S. aureus, P.
aeruginosaPM Bone Local 3 nr nr nr/nr Biotech [53]
P. aeruginosa Bone Local 1
Success for
bacterial
clearance†
Yes na/nr Biotech [54]
E. coli; Proteus;
S. aureus;
P. aeruginosa;
Streptococcus;
Enterococcus
Burns, ulcers,
wounds Topical; sc
234: (27; 90;
94; 23)
Overall high
success rate;
varied by study
Varied
with
study
Varied with
study/nr
Commercial;
unspecified
Review of 4
cases in
Russian
[55]
P. aeruginosa Aortic valvegraft
Direct via
fistula 1 Success Yes na/nr Academic [43]
A. baumanii
Post-operative
cranial
infection
iv 1
Infection site
cleared; blood
cultures
negative†
No Treatmentdiscontinued/nr Military [56]
S. aureus Chronic skininfection Topical; oral 1
Decreased
bacterial load;
improved
clinical
condition
No Prolongedtreatment/Yes (PS)
Commercial
(Eliava) [34]
A. baumanii Necrotizingpancreatitis iv; local 1 Success Yes na/Yes (PS)
Environ.,
military;
biotech;
phage bank
[57]
P. aeruginosa
Infected
wound/
septicemia
iv; local 1
Wounds
remained
colonized, blood
cultures were
negative†
Int
Bacteremia
resolved, but local
infection
persisted/nr
Military [58]
P. aeruginosa Bacteremia iv 1
Bacteremia
eradicated twice;
subsequent
regrowth †
Yes
Slow bacterial
regrowth/PRV
likely
Military [44]
S. aureus
Diabetic toe
ulcer
infection
Topical 6 Success; avoidedamputation nr na/nr
Commercial
(Eliava) [59]
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Table 1. Cont.
Pathogen Infection Admin Route N* ClinicalOutcome AB (N*)
Failure
/PRV+
Phage
Source Ref.
S. aureus Cornealabscess
Topical, nasal,
iv 1 Success nr na/nr
Commercial
(Eliava) [32]
P. aeruginosa;
S. aureusPM
Burn wound
infections Topical 9
Modest
reduction in
bacterial load for
8 patients
Just prior nr/nr Military [60]
Staphylococcus;
Enterococcus;
Pseudomonas;
E. coli; Proteus;
Enterococcus;
etcPM
UTI;
urogenital;
soft tissue;
skin;
orthopedic;
respiratory;
bacteremia;
etc.
Topical, oral,
rectal, vaginal,
inhaled
157
Good clinical
outcomes for
44% of patients
(success for 18%)
Yes (29%)
Inadequate
response for 60%
of patients/Yes
In-house [40]
P. aeruginosa UTI Local inbladder 1 Success Yes na/No
Commercial
(Eliava) [47]
Enterococcus
faecalis Prostatitis Rectal 3 Success No na/nr In-house [36]
S. aureus GI Carrierstatus Oral 1 Success No na/nr In-house [35]
P. aeruginosa Burn wound Topical 1 Successfulgrafting Yes na/nr Academic [61]
S. aureus Wounds Topical 2 Success Yes na/nr Commercial [62]
S. aureus;
E. coli;
P. aeruginosa;
Klebsiella;
etcPM
Septicemia Oral 94 85% success rate Yes(n = 71)
Phage ineffective
for 15% of
patients/nr
In-house [39]
Staphylococcus;
E. coli; Proteus;
Streptococcus;
P. aeruginosa PM
Venous
ulcers and
wounds
Topical 96 70% healing Yes
No clinical
improvement for
5 patients
Commercial [63]
S. aureus; E. coli;
P. aeruginosa;
Klebsiella PM
Various
infections in
cancer
patients
Oral, local 20 Healing in allpatients nr na/nr In-house [38]
S. aureus; E. coli;
Proteus;
P. aeruginosa;
Klebsiella;
EnterobacterPM
Septicemia;
ENT; UTI;
meningitis;
respiratory;
wounds;
bone; etc.
Oral; topical;
local 1307
Full recovery
86%; 11%
transient
improvement
nr
No effect in 3.8%
of study
population
(n = 50)
In-house [37]
* Number patients in study; AB: Concomitant antibiotic treatment with number of patients in (); PRV: Phage-resistant
variants reported; PM includes polymicrobial infections; GI: Gastrointestinal; ENT: Ear Nose Throat; 2◦ Secondary;
iv: intravenous; Int: intermittent; † Deceased; PS: Phage Substitution; sc: subcutaneous; na: not applicable; nr: not
reported; Environ: Environmental.
4. Sources and Availability of Phages for cPT
An essential prerequisite for cPT is the availability of phages active against the patient isolate
that can then be sufficiently purified to support clinical application. While evident, this can be a
limiting factor for cPT considering both the high level of specificity of phage–bacterial interactions and
time-to-treatment constraints for acute infections. Possible sources of phages for cPT are summarized
below, all of which have contributed by varying extents to cPT efforts.
4.1. Environmentally-Sourced Phages
Phages are naturally present in abundance from environmental samples, particularly in
bacteria-rich environments, such as sewage or from infections themselves, and natural environments
have been the primary source for all phages used in cPT to date [64]. However, starting from this
point entails phage isolation, propagation, and characterization that can delay treatment considerably,
and requires research infrastructure and expertise. Rare or less-studied pathogens may necessitate
environmental isolation of new phages, whereas phages against well-known pathogens (e.g., S. aureus,
P. aeruginosa, E. coli) are already widely available.
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4.2. Academically-Sourced Phages
Phages are the subject of fundamental and translational research in numerous academic laboratories
around the world. As such, phages sourced from academic labs often offer the benefit of additional
characterization, such as genome sequencing, host range analysis, and in vitro/in vivo studies that
can provide further information to support their use for cPT. Examples of cPT cases that used phages
sourced from academic labs include Schooley et al. [57] and Chan et al. [43]. In addition to academic
labs, phages can also be sourced from established phage banks or repositories, some of which provide
phages across international borders. Examples of phage banks include the Félix d’Hérelle Reference
Center for Bacterial Viruses at the University of Laval [65], the Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures [66] and the Bacteriophage Bank of Korea [67]. Phages
sourced from such banks are also often well-characterized, but may incur standard purchasing costs,
while academically-sourced phages tend to be supplied pro bono. Large phage banks can provide
the benefit of wider pathogen coverage, while some academic phage collections only include phages
against one or a select few pathogens. In addition to large phage banks that serve the international
community, other phage banks are intended to supply phages for in-house or local cases. For instance,
the collection at the PTU contains over 500 phages that cover 15 bacterial pathogens; however, their
phages have not been reported for cPT outside of Poland [40]. Both academically- and bank-sourced
phages may be liable to intellectual property (IP) constraints, though to different degrees, or require a
material transfer agreement (MTA) that limits and delineates the use of the phage(s) supplied.
4.3. Phage Products in Clinical Development
Phages are progressively being developed for clinical use by biotech companies. Such companies as
Pherecydes Pharma (France), Ampliphi Biosciences (US, Australia), and Adaptive Phage Therapeutics
(US) have participated in the supply and preparation of phages for cPT patients [52–54,57]. Phages
from clinical developers are well-suited for cPT, but phage biotechs understandably retain the right to
decline phage supply in consideration of their capacity and business interests.
4.4. Eastern European Phage Products
Commercially-available phages and phage preparations from Eastern European countries are an
additional phage source that have been used in clinical trials [16] and in compassionate treatments, both
within countries where they exist as registered products and in Western countries [32–34,45–47,51,55].
While standard commercial preparations have a predefined composition of phages, the Eliava Institute
offers personalized [34,47] or adapted phage compositions [50] that have been used in Tbilisi or sent to
other countries such as France, the US, or Australia. However, the use of commercial preparations
from Eastern Europe for cPT in countries where phage therapy is not approved may, or may not, lead
to importation or approval difficulties depending on regulatory adherence and requirements.
4.5. Crowd-Sourcing Phages
The importance of phages, whatever the source, for cPT is that they have activity against the
patient isolate, can be purified and formulated for safe administration, and are readily available to
conduce punctual treatment. The need for coordinated phage sharing was documented within a cPT
case for the treatment of a multidrug-resistant A. baumannii infection with phages [57]. In this case, a
total of nine phages from three different sources were required, and the effort was largely coordinated
by the patient’s wife via email and social media outlets due to the absence of established or official
channels. Following this case, in 2017, an initiative to organize such sharing was founded called Phage
Directory (https://phage.directory) [68]. One focus of this initiative is to keep a register of academic
phage researchers, phage banks, and phage companies that are willing to contribute phages for cPT
in order to locate active phages in the most time-efficient manner. For example, in late 2018, Phage
Directory helped coordinate the sourcing of Klebsiella pneumoniae phages for a patient in Helsinki,
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Finland by sending an electronic alert to its network of registered labs and phage collections. This effort
resulted in >175 phages being contributed by ten different groups over the span of three weeks, all of
which were tested against the patient’s isolate [31]. As of January 2019, there were 36 academic phage
laboratories and one phage bank registered on Phage Directory, representing more than 20 different
countries with phages covering more than 32 host genera (Figure 2). While this sharing network may
be less important for established centers or for those with direct access to large phage collections, it
certainly facilitates access for geographically-removed patients or physicians without phage research
support or established connections.
Figure 2. Geographic distribution of organizations (grouped by type) that have either previously
participated in cPT cases or demonstrated intent to do so in the future through registration with Phage
Directory (numbers current as of January 2019). Phage organizations not having yet contributed to cPT
are not listed here. SME: Small- and medium-sized enterprises.
4.6. Logistical Constraints
Phage sharing still requires the shipping of bacterial strains and/or phages to various locations
across the world; often phage biotechs or phage banks prefer bacterial strains to be shipped to them
for sensitivity testing, whereas academics have been more willing to send phages directly to other
researchers. From a regulatory point of view, shipping phages does not raise biosafety concerns.
However, shipping pathogenic bacteria does and is subject to pathogen transport regulations regarding
labeling, packaging, and documentation. In either situation, this step for cPT is time-consuming and
expensive, and represents a point of intervention for simplifying cPT. The ability to centralize stock of
phages available for cPT or to perform on-site susceptibility testing would reduce costs, standardize
susceptibility testing, and reduce time-to-treatment for cPT and clinical trials alike.
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5. Beyond Availability
Active phages are indeed indispensable for cPT, but several subsequent considerations need to be
addressed in order to assure a sound therapy. How phages are transported, amplified, purified, and
formulated into clinically-applicable formulations remains variable between cPT cases. These processes
require the oversight of, and close collaboration between, competent phage scientists and physicians.
Disorganization is a risk factor for errors to arise throughout this process, and measures must be taken
so as not to compromise to the integrity of the phage product and subsequent therapy. Verifying phage
viability, compatibility with medical devices (such as tubing or nebulizers), and sustained activity
against a patient’s infection throughout treatment are not systematically included for cPT, although
they are important factors for achieving intended therapeutic benefits. Compassionate use is not
subject to consistent procedures, and the employment of non-standardized methods for sensitivity
testing, purification, or formulation could contribute to variable treatment outcomes that may be
difficult to explain without thorough analysis. Phage therapy walks a thin wire for retaining support
to becoming part of modern medicine due to the historical hangover of inconsistent observations
in early trials, which continues to cast doubt on the potential of phage therapy today (reviewed
in [69–71]). Another risk for cPT treatment is that candidate patients often have confounding medical
conditions that complicate prognosis, although phage administration has never been linked to cause of
mortality [44,56]. These considerations make the effort to ensure that cPT is consistent and cooperative
all the more important.
However well-coordinated these processes become, the cost of providing cPT treatment is a
constraint on its scalability. Financial estimates for production costs and manpower needed on a
per-case basis are difficult to come by, but have ranged in the tens of thousands of US dollars in
countries where phage therapy does not have a legal framework (personal communications). cPT is
currently provided at no cost to the patient or treating institution in cases of cPT in the US, France, or
Australia; a model with little financial viability for either small biotechs or research labs. However,
cPT does not represent an avenue for commercialization. As clinical trials open, it is thought that
more patients will be able to access treatments through expanded access schemes or even through
participation in ongoing trials. The most scalable option is indeed to obtain marketing authorizations
for phage products, which, in a catch-22 situation, does little to address the issue of the current medical
need for cPT now.
On a final note, inconsistent, incomplete, or a lack of cPT reporting altogether is a missed
opportunity for gaining a better understanding of the antibacterial activity of phages in humans and
for further developing human phage therapy. The last phrase of Article 37 iterates the importance of
recording information gleaned from compassionate use cases and making it publicly available [18].
However, cPT reporting is frequently neglected or delayed for long periods of time following treatment,
with traditional news and social media-based reporting often outpacing peer-reviewed publications.
Data gathering has been identified as a problem with compassionate programs [72], which is further
complicated when compassionate treatment is provided by multiple sources, as in the case with
cPT, instead of a singular manufacturer. A better-structured, data-supported coordination of cPT
would enable this treatment option to not only become more widespread and ensure safer practices
for patients, but also to provide invaluable information to help refine future phage treatments.
The focus of compassionate treatment is unquestionably to provide benefit to the patient, but in
consideration of the higher success rate with cPT compared to meager RCT results, it is both wasteful
and borderline unethical to not thoroughly record and analyze non-efficacy data from cPT cases, such
as doses, frequency, or changes to phage sensitivity profiles. Information including pharmacokinetics,
concomitant treatment with antibiotics, and the apparition of phage-resistant variants from cPT would
be extremely useful in shaping future phage therapy endeavors and avoiding the clinical futility that
has been associated with recent phage RCTs. A detailed set of suggested criteria that phage research
and therapy should report has been proposed by Abedon [73]. Here we have presented several
generalities that should be addressed for cPT, which then next requires a practical proposal to be
Viruses 2019, 11, 343 10 of 14
formulated, supported, and adhered to by multiple stakeholders for the creation of clear policy and
actual implementation.
6. Conclusions
The duration of time until approved alternatives to antibiotics become available is unreassuringly
unknown. Traditional drug development pipelines estimate four to ten years for widespread marketing
and distribution of any new medicine or therapy, leaving approved phage products something for
the future. This substantial lag time between current need and the earliest foreseeable approvals for
new antibacterials leaves a considerable number of patients in a highly precarious situation: Reports
estimate that approximately 700,000 deaths are caused by antibiotic resistance each year already [74],
and claim an even higher number of disability-adjusted life-years and financial burden [75]. The success
rates of the cPT cases that have been reported on to date, as well as the willingness of the phage
community to participate in cPT efforts for critically-ill patients, emphasizes the potential role that cPT
could play in filling this gap between faltering antibiotics and the development of viable alternatives.
However, the case reports of cPT over the past decade have addressed only a negligible proportion
of antibiotic-resistant cases and remain geographically concentrated around experimental centers
or related to a small number of physicians and researchers with the required know-how. The most
impactful way to address antibiotic resistance would be to generate efficacy data through clinical trials
that would lead to marketing approvals. In the meantime, with better organizing of cPT in terms of
phage availability, logistics, and data reporting, progress can be made in the here and now toward
alleviating clinical failures due to antibiotic resistance.
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